Boston Scientific (BSX) Projected to Post Quarterly Earnings on Wednesday

Boston Scientific (NYSE:BSX - Get Free Report) will likely be announcing its earnings results before the market opens on Wednesday, April 23rd. Analysts expect the company to announce earnings of $0.67 per share and revenue of $4.57 billion for the quarter. Boston Scientific has set its Q1 2025 guidance at 0.660-0.680 EPS and its FY 2025 guidance at 2.800-2.870 EPS.Individual that are interested in registering for the company's earnings conference call can do so using this link.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, analysts expect Boston Scientific to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Boston Scientific Stock Down 0.2 %

Shares of NYSE:BSX traded down $0.17 during midday trading on Friday, reaching $95.08. The company had a trading volume of 6,672,959 shares, compared to its average volume of 6,370,413. Boston Scientific has a 1-year low of $66.80 and a 1-year high of $107.17. The stock has a market cap of $140.63 billion, a PE ratio of 76.06, a P/E/G ratio of 2.79 and a beta of 0.73. The business's 50 day moving average price is $99.68 and its 200 day moving average price is $94.26. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BSX. Royal Bank of Canada boosted their target price on shares of Boston Scientific from $105.00 to $116.00 and gave the company an "outperform" rating in a research report on Thursday, February 6th. Morgan Stanley raised their target price on Boston Scientific from $100.00 to $120.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. Needham & Company LLC upgraded Boston Scientific from a "hold" rating to a "buy" rating and set a $113.00 price target on the stock in a report on Wednesday. UBS Group upped their price objective on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Finally, Raymond James boosted their price objective on Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. One analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $110.22.

Insider Activity

In other news, CFO Daniel J. Brennan sold 67,333 shares of the business's stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the transaction, the chief financial officer now directly owns 225,808 shares of the company's stock, valued at approximately $23,764,033.92. The trade was a 22.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $104.25, for a total transaction of $487,368.75. Following the completion of the transaction, the executive vice president now directly owns 28,454 shares of the company's stock, valued at approximately $2,966,329.50. The trade was a 14.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 133,183 shares of company stock valued at $13,948,476. Insiders own 0.50% of the company's stock.

Institutional Investors Weigh In On Boston Scientific

An institutional investor recently raised its position in Boston Scientific stock. Brighton Jones LLC raised its holdings in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 0.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 27,376 shares of the medical equipment provider's stock after acquiring an additional 226 shares during the quarter. Brighton Jones LLC's holdings in Boston Scientific were worth $2,445,000 as of its most recent SEC filing. 89.07% of the stock is currently owned by institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.